Fig. 5: AMP-CpG immunization induces robust T cell responses to multiple variants of SARS-CoV-2 in NHPs. | npj Vaccines

Fig. 5: AMP-CpG immunization induces robust T cell responses to multiple variants of SARS-CoV-2 in NHPs.

From: Amphiphile-CpG vaccination induces potent lymph node activation and COVID-19 immunity in mice and non-human primates

Fig. 5

Rhesus macaques (n = 2/3) were immunized at week 0 and 4 with 140 µg WH-01 RBD protein admixed with either 5 mg or 10 mg of AMP-CpG, or 140 µg full WH-01 Spike protein admixed with AMP-CpG at 5 mg. PBMCs were collected at baseline and week 6 for T cell response assessment. a Schema showing animal dosing and experimental schedule. b, c PBMCs were stimulated at 0 and 6 weeks with WH-01 RBD OLPs or with VOC OLPs at 6 weeks prior to analysis by IFNγ ELISpot assay. Shown are IFNγ SFCs per 1 × 106 PBMCs. d–g PBMCs were stimulated with WH-01 OLPs prior to analysis for intracellular cytokines by flow cytometry. Shown are frequencies of total (d, f) and individual IL-2, TNFα, IFNγ cytokine producing (e, g) CD8+ (d, e) and CD4+ T cells (f, g). Values depicted are mean ± standard deviation. *p < 0.05 by two-sided Mann-Whitney test (b, d, f), or paired one-way ANOVA followed by Tukey’s (c) or Dunnett’s (e, g) post-hoc analysis applied to cytokine+ T cell frequencies. LN lymph node, B baseline.

Back to article page